Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir
Alimentary Pharmacology & Therapeutics2018Vol. 49(2), pp. 218–228
Citations Over TimeTop 10% of 2018 papers
Ming‐Te Kuo, Tsung‐Hui Hu, Chao‐Hung Hung, Jing‐Houng Wang, Sheng‐Nan Lu, Kai‐Lung Tsai, Chien‐Hung Chen
Abstract
HBV relapse occurs sooner and is more severe after cessation of TDF than after cessation of ETV.
Related Papers
- → 542 THE ENTEBE STUDY: SAFETY AND EFFICACY OF ENTECAVIR PLUS TENOFOVIR IN ADULTS WITH CHRONIC HEPATITIS B AND PREVIOUS NUCLEOS(T)IDE TREATMENT FAILURE(2012)
- → P1046 ENTECAVIR AND TENOFOVIR HAVE A COMPARABLE EFFICACY IN TREATMENT OF NUCLEOS(T)IDE ANALOGUE NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A REAL LIFE EXPERIENCE(2014)
- → Sa1503 - Safety and Efficacy of Switching Entecavir to Tenofovir Versus Tenofovir Treatment in Patients with Chronic Hepatitis B: A Comparative Study(2018)
- → WED-418 A national multicenter study on initial antiviral treatment preferences on chronic hepatitis B: Entecavir versus Tenofovir disoproxil fumarate(2024)
- → OS-123 Progression and risk factors after treatment with tenofovir or entecavir for chronic hepatitis B based on a multistate modeling approach(2024)